Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02943473 · OUTCOME

Number of Patients Without Symptomatic Myeloma

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients · Source last updated 2020-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
up to 1 year

What was measured

Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.

Groups in this outcome

Ibrutinib

Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis Ibrutinib: Ibrutinib is a type of drug called a "kinase inhibitor." Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ibrutinib7

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ibrutinib5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.
groups
  1. description
    Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis Ibrutinib: Ibrutinib is a type of drug called a "kinase inhibitor." Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.
    id
    OG000
    title
    Ibrutinib
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
up to 1 year
title
Number of Patients Without Symptomatic Myeloma
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice